Sandoz Group (OTCMKTS:SDZNY) versus Galectin Therapeutics (NASDAQ:GALT) Head-To-Head Comparison

Sandoz Group (OTCMKTS:SDZNY) and Galectin Therapeutics (NASDAQ:GALT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends.

Insider & Institutional Ownership

0.1% of Sandoz Group shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Sandoz Group and Galectin Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	1	0	3	3.50
Galectin Therapeutics	1	0	1	0	2.00

Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 340.00%. Given Galectin Therapeutics’ higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Sandoz Group.

Profitability

This table compares Sandoz Group and Galectin Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Galectin Therapeutics	N/A	N/A	-164.69%

Earnings and Valuation

This table compares Sandoz Group and Galectin Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$11.09 billion	3.26	$914.00 million	N/A	N/A
Galectin Therapeutics	N/A	N/A	-$30.84 million	($0.41)	-6.10

Sandoz Group has higher revenue and earnings than Galectin Therapeutics.

Volatility & Risk

Sandoz Group has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Summary

Sandoz Group beats Galectin Therapeutics on 6 of the 10 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Galectin Therapeutics

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.